Provided by Tiger Trade Technology Pte. Ltd.

AbCellera Biologics

13.91
-0.6800-4.66%
Post-market: 13.930.0200+0.14%19:57 EDT
Volume:7.79M
Turnover:109.84M
Market Cap:4.51B
PE:-25.50
High:14.65
Open:14.59
Low:13.79
Close:14.59
52wk High:15.02
52wk Low:2.75
Shares:324.00M
Float Shares:221.00M
Volume Ratio:1.29
T/O Rate:3.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5455
EPS(LYR):-0.4902
ROE:-17.30%
ROA:-10.39%
PB:5.03
PE(LYR):-28.38

Loading ...

Abcellera Biologics Inc. : Truist Securities Raises Target Price to $30 from $12

THOMSON REUTERS
·
Aug 11

Canada's Medexus Q1 Revenue Beats on Grafapex Strength

Reuters
·
Aug 11

AbCellera price target raised to $25 from $13 at JonesResearch

TIPRANKS
·
Aug 11

U.S. Stocks on the MOVE-Microsoft, Coastal Financial

Reuters
·
Aug 11

AbCellera Shares Jump on Trial Results Amid Interest in Menopause Drugs

Dow Jones
·
Aug 10

Sector Update: Healthcare Stocks Edge Higher Premarket Monday

MT Newswires Live
·
Aug 10

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Vanda (VNDA) and AbCellera Biologics (ABCL)

TIPRANKS
·
Aug 10

AbCellera Biologics' ABCL635 Meets Primary Efficacy Endpoints in Phase 2 Study

MT Newswires Live
·
Aug 10

U.S. Stocks on the MOVE-Apple, Barrick Mining, AbCellera Biologics

Reuters
·
Aug 10

AbCellera Posts Corporate Overview Highlighting Internal Antibody Pipeline and $565 Million-Plus Cash Position

Reuters
·
Aug 10

This Biotech's Drug Could Treat Hot Flashes. the Stock is up 32% on Good News.

Dow Jones
·
Aug 10

Abcellera Biologics Shares Rise 30.5% Premarket After Experimental Drug Reduces Hot Flashes in Mid-Stage Trial

THOMSON REUTERS
·
Aug 10

AbCellera's Menopause Drug Reduces Hot Flashes in Mid-Stage Trial

Reuters
·
Aug 10

AbCellera Says Phase 2 Trial Shows Abcl635 Cuts Menopausal Hot Flashes After Single Dose

Reuters
·
Aug 10

Abcellera Biologics - Phase 2 Results Show Best-in-Class Reductions in Vasomotor Symptoms After Single Dose

THOMSON REUTERS
·
Aug 10

Abcellera Announces Positive Top-Line Phase 2 Clinical Trial Results for Abcl635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

THOMSON REUTERS
·
Aug 10

Abcellera Biologics - Abcl635 Demonstrates Favorable Tolerability Profile

THOMSON REUTERS
·
Aug 10

Abcellera Biologics - Abcl635 Significantly Improves Sleep and Patient Global Impression of Change

THOMSON REUTERS
·
Aug 10

Abcellera Biologics - Abcl635 Well-Tolerated with no Serious or Severe Adverse Events

THOMSON REUTERS
·
Aug 10

Abcellera Biologics - Study Meets Primary Efficacy Endpoints with Significant Reductions at Week 4

THOMSON REUTERS
·
Aug 10